Small molecule · 328.3 Da

Tesofensine studies and research data

PepBank has 25 tesofensine studies with results. 16 of them gave tesofensine, with 90 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.

Searches 90 results and 57 papers. Newer studies from Europe PMC

Results in people

43% of 90 results

Results in animals

57% of 90 results

Results in lab cells

0% of 90 results

From computer models

0% of 90 results

The molecule

Tesofensine identity

Identifiers, parent molecule, targets and development stage, from curated data.

Tesofensine is a small molecule with four defined stereocentres. It inhibits monoamine reuptake. Saniona describes oral development for obesity with partner Medix. Its pipeline page states that Medix submitted an application to COFEPRIS. A favorable technical committee opinion is not marketing authorisation. Tesomet adds metoprolol, so combination results must remain distinct.

Kind: Small molecule
Formula: C₁₇H₂₃Cl₂NO
Identifiers: ChEMBLCHEMBL3989690 (opens in a new tab)PubChem CID11370864 (opens in a new tab)UNIIBLH9UKX9V1 (opens in a new tab)DrugBankDB06156 (opens in a new tab)CAS195875-84-4
Development: Phase 3NeuroSearch originator. Saniona and Productos Medix develop tesofensine.Saniona reports completion of a phase 3 obesity program and a submitted Mexican application. No Mexican approval was established. Source (opens in a new tab)

Targets

Molecular targets with action and evidence source
Target	Action	Evidence
Dopamine, serotonin and noradrenaline transporters	Reuptake inhibitor	sponsor descriptionSource (opens in a new tab)

Structure

Structure from the identity record.

2D structure

Draws the structure in your browser with RDKit (about 2.3 MB, loaded once).

SMILES fromPubChem CID 11370864(opens in a new tab)

CCOC[C@H]1[C@H]2CC[C@H](N2C)C[C@@H]1C3=CC(=C(C=C3)Cl)Cl

Results by area

Tesofensine results by year and outcome

Counts are exact and come from studies that gave the peptide.

Studies by year

25 of 57 studies have results (44%), published 2004 to 2025. Top row: every study. Bottom row: studies with results about Tesofensine, by class. The rows use different scales.

Studies
Human
Animal
Lab
Computer model
Natural levels, tool or combination only

Studies57 in all, 2001 to 2026

Studies with results25 in all, 2004 to 2025

Retracted studies are left out. A study with results in two classes counts in both.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

What the studies measured

People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.

Tesofensine studies on weight and appetite

36 results · people 12 · animals 24 · lab 0

Top 5 of 36 results

In overweight or moderately obese men, tesofensine increased satiety ratings compared with placebo.International journal of obesity, 2010
In overweight or moderately obese men, tesofensine reduced body weight more than placebo.International journal of obesity, 2010
In trial participants, tesofensine increased combined satiety scores dose-dependently at week 12.Obesity, 2012
In early Parkinson disease, decreased body weight was common with tesofensine 1.0 mg.Movement disorders, 2007
In overweight or moderately obese men, tesofensine increased fullness ratings compared with placebo.International journal of obesity, 2010

Tesofensine studies on daily life and fitness

9 results · people 9 · animals 0 · lab 0

Top 3 of 9 results

In advanced Parkinson disease, tesofensine 0.5 mg improved daily activity and motor scores more than placebo.Archives of neurology, 2008
In advanced Parkinson disease, NS 2330 given alone or with levodopa did not change symptom scores versus placebo.Movement disorders, 2004
In early Parkinson disease, tesofensine 0.25 mg did not significantly improve scores versus placebo at week 14.Movement disorders, 2007

Tesofensine studies on side effects

11 results · people 8 · animals 3 · lab 0

Top 5 of 11 results

In advanced Parkinson disease, tesofensine caused more neuropsychiatric adverse events than placebo, especially at higher dosages.Archives of neurology, 2008
In advanced Parkinson disease, participants tolerated NS 2330 well.Movement disorders, 2004
In advanced Parkinson disease, tesofensine caused more gastrointestinal adverse events than placebo, especially at higher dosages.Archives of neurology, 2008
In early Parkinson disease, elevated heart rate was common with tesofensine 1.0 mg.Movement disorders, 2007
In early Parkinson disease, dry mouth was a commonly reported adverse event with tesofensine.Movement disorders, 2007

Tesofensine studies on mood, stress and behavior

4 results · people 4 · animals 0 · lab 0

Top 3 of 4 results

In recreational stimulant users, tesofensine did not differ significantly from placebo on the reported subjective measures.Clinical pharmacology and therapeutics, 2010
In recreational stimulant users, tesofensine effects were lower than D-amphetamine on all primary and most secondary subjective measures.Clinical pharmacology and therapeutics, 2010
In recreational stimulant users, tesofensine effects were either lower than or not different from those of bupropion or atomoxetine.Clinical pharmacology and therapeutics, 2010

Tesofensine studies on metabolism and nutrition

3 results · people 3 · animals 0 · lab 0

3 results

In overweight or moderately obese men, tesofensine did not significantly change total daily energy expenditure compared with placebo.International journal of obesity, 2010
In overweight or moderately obese men, tesofensine increased nighttime energy expenditure versus placebo after adjustment for body composition changes.International journal of obesity, 2010
In overweight or moderately obese men, tesofensine increased daily fat oxidation compared with placebo.International journal of obesity, 2010

Tesofensine studies on receptors and cell signals

13 results · people 1 · animals 12 · lab 0

Top 3 of 13 results

In a human PET study, tesofensine blocked more dopamine transporters at higher doses.European neuropsychopharmacology, 2014
In obese rats, acute tesofensine normalized accumbal dopamine levels.Pharmacology, biochemistry, and behavior, 2013
In obese rats, tesofensine reduced nucleus accumbens D2/D3 receptor availability compared with vehicle.European neuropsychopharmacology, 2012

Tesofensine studies on blood levels and clearance

1 result · people 1 · animals 0 · lab 0

1 result

In advanced Parkinson disease, higher tesofensine dosages produced higher blood concentrations.Archives of neurology, 2008

Tesofensine studies on sleep

1 result · people 1 · animals 0 · lab 0

1 result

In early Parkinson disease, insomnia was a commonly reported adverse event with tesofensine.Movement disorders, 2007

Tesofensine studies on brain and nerves

8 results · people 0 · animals 8 · lab 0

Top 3 of 8 results

In rats, chronic tesofensine increased BDNF gene expression in the hippocampal CA3 region.European journal of pharmacology, 2007
In rats, sub-chronic tesofensine did not increase BDNF gene expression in the hippocampal CA3 region.European journal of pharmacology, 2007
In rats, chronic tesofensine increased Arc gene expression in the hippocampal CA1 region.European journal of pharmacology, 2007

Tesofensine studies on heart and blood vessels

2 results · people 0 · animals 2 · lab 0

2 results

In rats, acute tesofensine increased blood pressure.Obesity, 2013
In rats, acute tesofensine increased heart rate.Obesity, 2013

Tesofensine studies on blood sugar

1 result · people 0 · animals 1 · lab 0

1 result

In obese rats, tesofensine reduced the insulin response to oral glucose more than pair feeding.European journal of pharmacology, 2010

Tesofensine studies on cholesterol and blood fats

1 result · people 0 · animals 1 · lab 0

1 result

In obese rats, tesofensine-associated fat reduction was accompanied by reduced plasma lipid levels.European journal of pharmacology, 2010

Trials and papers

Tesofensine trials

Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.

StatusPhase

14 trials match. Highest phase first. Data from ClinicalTrials.gov.

Trials on this page (14 of 14)

14 trials · 12 completed · 2 stopped early · 5 with posted results

Completed
Ongoing
Not yet recruiting
Stopped
Estimated dates (est.)
Results posted

20002005201020152020

Ph 2
Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's Disease
NCT00006077
Aug 2000 to Jul 2003
Ph 2
An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type
NCT00153010
Feb 2003 to Mar 2005 (primary)
Ph 2
A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Study of NS 2330 (Tesofensine) (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations
NCT00148512
Mar 2003 to Feb 2005
Ph 2
A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)
NCT00148486
Jun 2003 to Mar 2005 (primary)
Ph 2
Effect of Tesofensine on Weight Reduction in Patients With Obesity.
NCT00394667
Sept 2006 to Sept 2007
Ph 1/2
Effect of Tesofensine on Energy Balance in Humans.
NCT00428415
Mar 2007 to Dec 2007
Ph 2
Evaluation of Long Term Safety of Tesofensine in Patients With Obesity
NCT00481104
May 2007 to Nov 2008
Ph 2
Safety and Efficacy Study of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus
NCT02737891
Apr 2016 to Mar 2017
Ph 2
2016-003694-18
NCT03149445
30 Mar 2017 to 22 Jul 2019
Ph 1
Study to Investigate the Pharmacokinetic Profile
NCT03286829
18 Dec 2017 to 6 Feb 2018

14 trials · 12 completed · 2 stopped early · 5 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT03149445

Co-administration of Tesofensine/Metoprolol in Subjects With Prader-Willi Syndrome (PWS)

Sanionan = 1830 Mar 2017 to 22 Jul 2019

Confirmed Genetic Diagnosis of Prader-Willi Syndrome

Trial page ClinicalTrials.govUpdated 26 Feb 2024

CompletedPhase 2Results postedNCT03845075

48 Weeks, Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO)

Sanionan = 2125 Feb 2019 to 16 Oct 2020

Hypothalamic Injury-induced Obesity (HIO)

Trial page ClinicalTrials.govUpdated 13 Feb 2024

WithdrawnPhase 2NCT05147415

Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO)

Sanionan = 011 Nov 2021 to 9 Dec 2022

Hypothalamic Obesity

Trial page ClinicalTrials.govUpdated 13 Dec 2022

WithdrawnPhase 2NCT05198362

Study of Tesomet With Open-label Extension in Subjects With Prader-Willi Syndrome

Sanionan = 028 Dec 2021 to 9 Dec 2022

Prader-Willi Syndrome

Trial page ClinicalTrials.govUpdated 13 Dec 2022

CompletedPhase 2Results postedNCT02737891

Safety and Efficacy Study of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus

Sanionan = 60Apr 2016 to Mar 2017

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 14 May 2020

CompletedPhase 2NCT00148486

A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)

Boehringer Ingelheimn = 261Jun 2003 to Mar 2005 (primary)

Parkinson Disease

Trial page ClinicalTrials.govUpdated 29 Oct 2013

CompletedPhase 2NCT00148512

A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Study of NS 2330 (Tesofensine) (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations

Boehringer Ingelheimn = 254Mar 2003 to Feb 2005

Parkinson Disease

Trial page ClinicalTrials.govUpdated 29 Oct 2013

CompletedPhase 2NCT00153010

An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type

Boehringer Ingelheimn = 430Feb 2003 to Mar 2005 (primary)

Alzheimer Disease

Trial page ClinicalTrials.govUpdated 29 Oct 2013

CompletedPhase 2NCT00394667

Effect of Tesofensine on Weight Reduction in Patients With Obesity.

NeuroSearch A/Sn = 200Sept 2006 to Sept 2007

Obesity

Trial page ClinicalTrials.govUpdated 22 Apr 2013

CompletedPhase 2NCT00481104

Evaluation of Long Term Safety of Tesofensine in Patients With Obesity

NeuroSearch A/Sn = 140May 2007 to Nov 2008

Obesity

Trial page ClinicalTrials.govUpdated 4 Jul 2011

CompletedPhase 1/2NCT00428415

Effect of Tesofensine on Energy Balance in Humans.

NeuroSearch A/Sn = 32Mar 2007 to Dec 2007

Obesity

Trial page ClinicalTrials.govUpdated 5 Mar 2008

CompletedPhase 2NCT00006077

Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's Disease

National Institute of Neurological Disorders and Stroke (NINDS)n = 50Aug 2000 to Jul 2003

Parkinson's Disease

Trial page ClinicalTrials.govUpdated 4 Mar 2008

CompletedPhase 1Results postedNCT03488719

A Study to Examine the Effect of Tesofensine and Metoprolol on the 24-hour Mean Heart Rate

Sanionan = 3711 Jul 2018 to 6 Jun 2019

Phase 1

Trial page ClinicalTrials.govUpdated 9 Feb 2024

CompletedPhase 1Results postedNCT03286829

Study to Investigate the Pharmacokinetic Profile

Sanionan = 6018 Dec 2017 to 6 Feb 2018

Healthy Male Subjects

Trial page ClinicalTrials.govUpdated 14 May 2020

Papers

Studies on this peptide. Some have results. The others have none yet.

Sort

Design

57 studies match. Retracted studies are left out.

Showing 24 of 57 studiesquery qry_96189b397d97f36cface0646

Studies with results

25 studies in all, 12 on this page

Not a test of Tesofensine alone · 2022

9 results

Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity.

Huynh et al. 2022European journal of endocrinologycited by 38

PMID 35294397PMC9175551DOI 10.1530/eje-21-0972PUB-35294397

CC BY9 results where Tesofensine was a tool, carrier or part of a combination

Download PDF See results (9)

Randomized controlled trial · 2004

4 results

Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease.

Bara-Jimenez et al. 2004Movement disorders : official journal of the Movement Disorder Societyn = 9cited by 37

PMID 15390018DOI 10.1002/mds.20124PUB-15390018

Rights unknown4 results where Tesofensine was given

Source link See results (4)

Randomized controlled trial · 2007

10 results

Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease.

Hauser et al. 2007Movement disorders : official journal of the Movement Disorder Societycited by 37

PMID 17149725DOI 10.1002/mds.21258PUB-17149725

Full text at the publisher10 results where Tesofensine was given

Publisher page See results (10)

Animal study (in vivo) · rat · 2010

9 results

Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat.

Axel et al. 2010Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacologycited by 37

PMID 20200509PMC3055463DOI 10.1038/npp.2010.16PUB-20200509

Rights unknown3 results where Tesofensine was given (plus 6 on tools or combinations, listed separately)

Source link See results (9)

Randomized controlled trial · 2010

7 results

The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men.

Sjödin et al. 2010International journal of obesity (2005)n = 32cited by 37

PMID 20479765DOI 10.1038/ijo.2010.87PUB-20479765

Rights unknown7 results where Tesofensine was given

Source link See results (7)

Animal study (in vivo) · rat · 2007

8 results

Expression of brain derived neurotrophic factor, activity-regulated cytoskeleton protein mRNA, and enhancement of adult hippocampal neurogenesis in rats after sub-chronic and chronic treatment with the triple monoamine re-uptake inhibitor tesofensine.

Larsen et al. 2007European journal of pharmacologycited by 36

PMID 17112503DOI 10.1016/j.ejphar.2006.10.029PUB-17112503

Full text at the publisher8 results where Tesofensine was given

Publisher page See results (8)

Randomized controlled trial · 2010

4 results

Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users.

Schoedel et al. 2010Clinical pharmacology and therapeuticsn = 52cited by 34

PMID 20520602DOI 10.1038/clpt.2010.67PUB-20520602

Full text at the publisher4 results where Tesofensine was given

Publisher page See results (4)

Randomized controlled trial · 2012

6 results

The effect of tesofensine on appetite sensations.

Gilbert et al. 2012Obesity (Silver Spring, Md.)cited by 32

PMID 21720440DOI 10.1038/oby.2011.197PUB-21720440

Rights unknown4 results where Tesofensine was given (plus 2 on tools or combinations, listed separately)

Source link See results (6)

Not a test of Tesofensine alone · 2008

6 results

Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach.

Lehr et al. 2008British journal of pharmacologycited by 31

PMID 17982477PMC2199391DOI 10.1038/sj.bjp.0707539PUB-17982477

Rights unknown6 results where Tesofensine was a tool, carrier or part of a combination

Source link See results (6)

Animal study (in vivo) · rat · 2010

10 results

The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant.

Hansen et al. 2010European journal of pharmacologycited by 30

PMID 20385125DOI 10.1016/j.ejphar.2010.03.026PUB-20385125

Full text at the publisher10 results where Tesofensine was given

Publisher page See results (10)

Not a test of Tesofensine alone · 2009

2 results

A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam.

Lehr et al. 2009Clinical pharmacokineticscited by 28

PMID 19705923DOI 10.2165/11313370-000000000-00000PUB-19705923

Full text at the publisher2 results where Tesofensine was a tool, carrier or part of a combination

Publisher page See results (2)

Randomized controlled trial · 2008

6 results

Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study.

Rascol et al. 2008Archives of neurologycited by 27

PMID 18474731DOI 10.1001/archneur.65.5.577PUB-18474731

Full text at the publisher6 results where Tesofensine was given

Publisher page See results (6)

More studies

29 studies in all, 12 on this page

PubMed tag: Review · 2018

Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon.

Srivastava et al. 2018Current obesity reportscited by 146

PMID 29504049DOI 10.1007/s13679-018-0300-4PUB-29504049

Full text at the publisher

Publisher page

PubMed tag: Review · 2012

Anti-obesity drugs: a review about their effects and their safety.

Derosa et al. 2012Expert opinion on drug safetycited by 129

Heal et al. 2014Neuropharmacologycited by 31

PMID 24953830DOI 10.1016/j.neuropharm.2014.06.012PUB-24953830

Full text at the publisher

Publisher page

No result for Tesofensine (1 study on this page, 3 in all)

These studies name Tesofensine but give no result for it (for example, the results concern another peptide in the study).

PubMed tag: Review, Comparative Study · 2014

New and emerging drug molecules against obesity.

George et al. 2014Journal of cardiovascular pharmacology and therapeuticscited by 44

PMID 24064009DOI 10.1177/1074248413501017PUB-24064009

Full text at the publisher

Publisher page

Newer studies

PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.

Tesofensine studies: 25 papers with results

Page 1 of 1

Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study.
Rascol O · Archives of neurology · 2008
Randomized controlled trial · 6 results
Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users.
Schoedel KA · Clinical pharmacology and therapeutics · 2010
Randomized controlled trial · 4 results
The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men.
Sjödin A · International journal of obesity (2005) · 2010
Randomized controlled trial · 7 results
Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease.
Bara-Jimenez W · Movement disorders : official journal of the Movement Disorder Society · 2004
Randomized controlled trial · 4 results
Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease.
Hauser RA · Movement disorders : official journal of the Movement Disorder Society · 2007
Randomized controlled trial · 10 results
The effect of tesofensine on appetite sensations.
Gilbert JA · Obesity (Silver Spring, Md.) · 2012
Randomized controlled trial · 6 results
[The effect of tesofensine on body weight and body composition in obese subjects--secondary publication].
Nielsen AL · Ugeskrift for laeger · 2009
Randomized controlled trial · 3 results
Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects: dopamine transporter occupancy as measured by PET.
Appel L · European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2014
Non-randomized trial · 4 results
Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat.
Axel AM · Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2010
Animal study (in vivo) · rat · 9 results
Expression of brain derived neurotrophic factor, activity-regulated cytoskeleton protein mRNA, and enhancement of adult hippocampal neurogenesis in rats after sub-chronic and chronic treatment with the triple monoamine re-uptake inhibitor tesofensine.
Larsen MH · European journal of pharmacology · 2007
Animal study (in vivo) · rat · 8 results
The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant.
Hansen HH · European journal of pharmacology · 2010
Animal study (in vivo) · rat · 10 results
Tesofensine induces appetite suppression and weight loss with reversal of low forebrain dopamine levels in the diet-induced obese rat.
Hansen HH · Pharmacology, biochemistry, and behavior · 2013
Animal study (in vivo) · rat · 8 results
Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats.
Bentzen BH · Obesity (Silver Spring, Md.) · 2013
Animal study (in vivo) · rat · 9 results
Triple monoamine inhibitor tesofensine decreases food intake, body weight, and striatal dopamine D2/D3 receptor availability in diet-induced obese rats.
van de Giessen E · European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2012
Animal study (in vivo) · rat · 10 results
Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons.
Perez CI · PloS one · 2024
Animal study (in vivo) · mouse and rat · 11 results
Sex-specific effects of appetite suppressants on stereotypy in rats.
Lopez A · PloS one · 2025
Animal study (in vivo) · rat · 4 results
Weight Loss, Improved Body Composition and Fat Distribution by Tesomet in Acquired Hypothalamic Obesity
Huynh K · Journal of the Endocrine Society · 2021
Not a test of Tesofensine alone · 17 results
ODP350 Safety and Efficacy of Tesomet over 48 Weeks of Treatment: Results From a 24-Week Phase 2, Randomized, Double-Blind Study With 24 Week Open-Label Extension in Adults With Hypothalamic Obesity
Journal of the Endocrine Society · 2022
Not a test of Tesofensine alone · 14 results
Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity.
Huynh K · European journal of endocrinology · 2022
Not a test of Tesofensine alone · 9 results
Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease.
Lehr T · British journal of clinical pharmacology · 2007
Not a test of Tesofensine alone · 8 results
Semi-mechanistic population pharmacokinetic drug-drug interaction modelling of a long half-life substrate and itraconazole.
Lehr T · Clinical pharmacokinetics · 2010
Not a test of Tesofensine alone · 7 results
Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach.
Lehr T · British journal of pharmacology · 2008
Not a test of Tesofensine alone · 6 results
Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine.
Lehr T · The AAPS journal · 2010
Not a test of Tesofensine alone · 3 results
A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam.
Lehr T · Clinical pharmacokinetics · 2009
Not a test of Tesofensine alone · 2 results
Structural basis for pharmacotherapeutic action of triple reuptake inhibitors.
Li Y · Nature communications · 2025
Not a test of Tesofensine alone · 1 result

Status and safety

Regulatory and safety

Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.

Regulatory status by jurisdiction, with date and source
Jurisdiction	Body	Status	As of	Source
US	FDA	The openFDA active ingredient search returned no matches. This confirms no matching entry in this database, not worldwide absence of approval.	22 Oct 2026	api.fda.gov (opens in a new tab)
EU	EMA	No authorised exact product match was found in the EMA central medicine catalogue. National authorisations are outside this check.	22 Oct 2026	ema.europa.eu (opens in a new tab)
Sport	WADA	Banned in sport (WADA S6.B) Tesofensine is named among specified stimulants.	2026 List	wada-ama.org (opens in a new tab)
Mexico	Note	Not approved in Mexico. Medix submitted a marketing application to COFEPRIS. Saniona reported on 2024-11-06 that COFEPRIS had not yet approved it, and its interim report for the first quarter of 2026 says the application is under review. A favorable 2023 technical committee opinion is not an approval. The COFEPRIS register was not searched directly.	22 Oct 2026	inderes.se (opens in a new tab)

Safety outcomes

15 safety results for Tesofensine.

Human evidence· 10

In advanced Parkinson disease, adding NS 2330 to levodopa did not appear to alter levodopa-associated dyskinesia severity versus placebo.
Randomized controlled trialn = 9
In advanced Parkinson disease, NS 2330 was well tolerated.
Randomized controlled trialn = 9
In early Parkinson disease, tesofensine was generally well tolerated.
Randomized controlled trialn not reported
In early Parkinson disease, constipation was among the most commonly reported tesofensine adverse events.
Randomized controlled trialn not reported
In early Parkinson disease, insomnia was among the most commonly reported tesofensine adverse events.
Randomized controlled trialn not reported
In early Parkinson disease, dry mouth was among the most commonly reported tesofensine adverse events.
Randomized controlled trialn not reported
In early Parkinson disease, decreased body weight was common with tesofensine 1.0 mg.
Randomized controlled trialn not reported
In early Parkinson disease, elevated heart rate was common with tesofensine 1.0 mg.
Randomized controlled trialn not reported

Animal evidence· 5

In rats, acute tesofensine increased heart rate.
Animal study (in vivo)rat
In rats, acute tesofensine increased blood pressure.
Animal study (in vivo)rat
In the rodent study, tesofensine caused few, if any, head-weaving stereotypies at therapeutic doses, unlike phentermine.
Animal study (in vivo)mice and rats
In rats, tesofensine elicited head-weaving only in females, at a lower extent than other dopaminergic agents.
Animal study (in vivo)rat
In rats, tesofensine was most frequently associated with orolingual dyskinesia.
Animal study (in vivo)rat

Doses studied · 21

The doses that these studies used. They are not recommendations.

0.5 mg dailyHuman
Species
human
Route
oral
Duration
14 weeks
Design
Randomized controlled trial
0.25 mg dailyHuman
Species
human
Route
oral
Duration
14 weeks
Design
Randomized controlled trial
2.0 mg daily for 7 days, then 1.0 mg daily for 7 daysHuman
Species
human
Route
Not reported
Duration
2 weeks
Design
Randomized controlled trial · n = 32
0.25 mg dailyHuman
Species
human
Route
Not reported
Duration
14 weeks
Design
Randomized controlled trial
0.5 mg dailyHuman
Species
human
Route
Not reported
Duration
14 weeks
Design
Randomized controlled trial
1.0 mg dailyHuman
Species
human
Route
Not reported
Duration
14 weeks
Design
Randomized controlled trial

Doses studied in the study results, as given in the studies.
Dose as reported	Class	Species	Route	Duration	Design
0.5 mg daily	Human	human	oral	14 weeks	Randomized controlled trial
0.25 mg daily	Human	human	oral	14 weeks	Randomized controlled trial
2.0 mg daily for 7 days, then 1.0 mg daily for 7 days	Human	human	Not reported	2 weeks	Randomized controlled trial · n = 32
0.25 mg daily	Human	human	Not reported	14 weeks	Randomized controlled trial
0.5 mg daily	Human	human	Not reported	14 weeks	Randomized controlled trial
1.0 mg daily	Human	human	Not reported	14 weeks	Randomized controlled trial

6 of 21 shown

PepBank is a research reference. Talk to a doctor before you use any peptide.

Data

Data and API

Data version, change history and code for this peptide.

Data version 30856030 Oct 2026

Peptide

Peptide id: PEP-000088
Peptide version: 4
Peptide hash: 2c55af7ab178356e…
Data version: 308560

Latest changes

27 Oct 2026UpdatedData version 256785
22 Oct 2026UpdatedData version 254581
21 Oct 2026UpdatedData version 226604
21 Oct 2026CreatedData version 213667

For developers

curl -s https://pepbank.io/v1/briefs/tesofensine

Evidence summary for Tesofensine: counts by class, key results with sources, notices, data version.

Peptide as JSON Evidence summary as JSON

Outcome group	Human	Animal	Lab	Computer model	Total
Exercise and physical functionNervous system and cognition	Human: 9 results from 3 studies: 3 decrease, 6 no significant change. Strongest design: Randomized controlled trial	No results	No results	No results	9
Appetite and food intakeMetabolic and weight	Human: 7 results from 2 studies: 5 increase, 1 decrease, 1 mixed. Strongest design: Randomized controlled trial	Animal: 12 results from 6 studies: 2 increase, 7 decrease, 2 no significant change, 1 not reported. Strongest design: Animal study (in vivo)	No results	No results	19
Adverse eventsWhole body	Human: 6 results from 3 studies: 2 increase, 1 no significant change, 3 not reported. Strongest design: Randomized controlled trial	Animal: 3 results from 2 studies: 1 decrease, 1 mixed, 1 not reported. Strongest design: Animal study (in vivo)	No results	No results	9
Body weightMetabolic and weight	Human: 5 results from 3 studies: 5 decrease. Strongest design: Randomized controlled trial	Animal: 12 results from 6 studies: 3 increase, 9 decrease. Strongest design: Animal study (in vivo)	No results	No results	17
Addiction, withdrawal and alcohol intakeNervous system and cognition	Human: 4 results from 1 study: 1 decrease, 1 no significant change, 2 mixed. Strongest design: Randomized controlled trial	No results	No results	No results	4
Energy expenditure and thermogenesisMetabolic and weight	Human: 3 results from 1 study: 2 increase, 1 no significant change. Strongest design: Randomized controlled trial	No results	No results	No results	3
Gastrointestinal adverse eventsGastrointestinal	Human: 2 results from 2 studies: 1 increase, 1 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	2
Receptor activity and mechanismNervous system and cognition	Human: 1 result from 1 study: 1 increase. Strongest design: Non-randomized trial	Animal: 12 results from 3 studies: 3 increase, 5 decrease, 1 no significant change, 1 mixed, 2 not reported. Strongest design: Animal study (in vivo)	No results	No results	13
PharmacokineticsPharmacology	Human: 1 result from 1 study: 1 increase. Strongest design: Randomized controlled trial	No results	No results	No results	1
SleepSleep	Human: 1 result from 1 study: 1 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	1
NeuroprotectionNervous system and cognition	No results	Animal: 8 results from 1 study: 4 increase, 4 no significant change. Strongest design: Animal study (in vivo)	No results	No results	8
Blood pressureCardiovascular	No results	Animal: 1 result from 1 study: 1 increase. Strongest design: Animal study (in vivo)	No results	No results	1

Outcome group	Human	Animal	Lab	Computer model	Total
Exercise and physical functionNervous system and cognition	Human: 9 results from 3 studies: 3 decrease, 6 no significant change. Strongest design: Randomized controlled trial	No results	No results	No results	9
Appetite and food intakeMetabolic and weight	Human: 7 results from 2 studies: 5 increase, 1 decrease, 1 mixed. Strongest design: Randomized controlled trial	Animal: 12 results from 6 studies: 2 increase, 7 decrease, 2 no significant change, 1 not reported. Strongest design: Animal study (in vivo)	No results	No results	19
Adverse eventsWhole body	Human: 6 results from 3 studies: 2 increase, 1 no significant change, 3 not reported. Strongest design: Randomized controlled trial	Animal: 3 results from 2 studies: 1 decrease, 1 mixed, 1 not reported. Strongest design: Animal study (in vivo)	No results	No results	9
Body weightMetabolic and weight	Human: 5 results from 3 studies: 5 decrease. Strongest design: Randomized controlled trial	Animal: 12 results from 6 studies: 3 increase, 9 decrease. Strongest design: Animal study (in vivo)	No results	No results	17
Addiction, withdrawal and alcohol intakeNervous system and cognition	Human: 4 results from 1 study: 1 decrease, 1 no significant change, 2 mixed. Strongest design: Randomized controlled trial	No results	No results	No results	4
Energy expenditure and thermogenesisMetabolic and weight	Human: 3 results from 1 study: 2 increase, 1 no significant change. Strongest design: Randomized controlled trial	No results	No results	No results	3
Gastrointestinal adverse eventsGastrointestinal	Human: 2 results from 2 studies: 1 increase, 1 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	2
Receptor activity and mechanismNervous system and cognition	Human: 1 result from 1 study: 1 increase. Strongest design: Non-randomized trial	Animal: 12 results from 3 studies: 3 increase, 5 decrease, 1 no significant change, 1 mixed, 2 not reported. Strongest design: Animal study (in vivo)	No results	No results	13
PharmacokineticsPharmacology	Human: 1 result from 1 study: 1 increase. Strongest design: Randomized controlled trial	No results	No results	No results	1
SleepSleep	Human: 1 result from 1 study: 1 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	1
NeuroprotectionNervous system and cognition	No results	Animal: 8 results from 1 study: 4 increase, 4 no significant change. Strongest design: Animal study (in vivo)	No results	No results	8
Blood pressureCardiovascular	No results	Animal: 1 result from 1 study: 1 increase. Strongest design: Animal study (in vivo)	No results	No results	1

Tesofensine studies and research data

Tesofensine identity

Targets

Structure

2D structure

Tesofensine results by year and outcome

What the studies measured

Tesofensine studies on weight and appetite

Tesofensine studies on daily life and fitness

Tesofensine studies on side effects

Tesofensine studies on mood, stress and behavior

Tesofensine studies on metabolism and nutrition

Tesofensine studies on receptors and cell signals

Tesofensine studies on blood levels and clearance

Tesofensine studies on sleep

Tesofensine studies on brain and nerves

Tesofensine studies on heart and blood vessels

Tesofensine studies on blood sugar

Tesofensine studies on cholesterol and blood fats

Tesofensine trials

Co-administration of Tesofensine/Metoprolol in Subjects With Prader-Willi Syndrome (PWS)

48 Weeks, Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO)

Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO)

Study of Tesomet With Open-label Extension in Subjects With Prader-Willi Syndrome

Safety and Efficacy Study of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus

A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)

A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Study of NS 2330 (Tesofensine) (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations

An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type

Effect of Tesofensine on Weight Reduction in Patients With Obesity.

Evaluation of Long Term Safety of Tesofensine in Patients With Obesity

Effect of Tesofensine on Energy Balance in Humans.

Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's Disease

A Study to Examine the Effect of Tesofensine and Metoprolol on the 24-hour Mean Heart Rate

Study to Investigate the Pharmacokinetic Profile

Papers

Studies with results

Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity.

Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease.

Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease.

Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat.

The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men.

Expression of brain derived neurotrophic factor, activity-regulated cytoskeleton protein mRNA, and enhancement of adult hippocampal neurogenesis in rats after sub-chronic and chronic treatment with the triple monoamine re-uptake inhibitor tesofensine.

Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users.

The effect of tesofensine on appetite sensations.

Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach.

The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant.

A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam.

Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study.

More studies

Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon.

Anti-obesity drugs: a review about their effects and their safety.

Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial.

Pharmacotherapies for obesity: past, current, and future therapies.

Pharmacological management of appetite expression in obesity.

Centrally Acting Agents for Obesity: Past, Present, and Future.

Neuropsychiatric adverse effects of centrally acting antiobesity drugs.

New approaches to the pharmacological treatment of obesity: can they break through the efficacy barrier?

Treatment of Parkinson's disease : what's on the horizon?

Serotonergic anti-obesity agents: past experience and future prospects.

Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease.

Dopamine reuptake transporter (DAT) "inverse agonism"--a novel hypothesis to explain the enigmatic pharmacology of cocaine.

New and emerging drug molecules against obesity.

Newer studies

Tesofensine studies: 25 papers with results

Regulatory and safety

Human evidence· 10

Animal evidence· 5

Doses studied · 21

Data and API

Peptide

Latest changes

For developers

Related peptides

Tesofensine results by year and outcome

Tesofensine studies on weight and appetite

Tesofensine studies on daily life and fitness

Tesofensine studies on side effects

Tesofensine studies on mood, stress and behavior

Tesofensine studies on metabolism and nutrition

Tesofensine studies on receptors and cell signals